Genetic, dietary, and inflammatory factors contribute to the etiology of major mood disorders (MMD), thus impeding the identification of specific biomarkers to assist in diagnosis and treatment. We tested association of vitamin D and inflammatory markers in 36 adolescents with bipolar disorder (BD) and major depressive disorder (MDD) forms of MMD and without MMD (non-mood control). We also assessed the overall level of inflammation using a cell-based reporter assay for nuclear factor kappa-B (NFκB) activation and measuring antibodies to oxidized LDL. We found that these factors were similar between non-mood and MMD youth. To identify potential biomarkers, we developed a screening immunoprecipitation-sequencing approach based on inflammatory brain glia maturation factor beta (GMFβ). We discovered that a homolog of GMFβ in human plasma is vitamin D-binding protein (DBP) and validated this finding using immunoprecipitation with anti-DBP antibodies and mass spectrometry/sequencing analysis. We quantified DBP levels in participants by western blot. DBP levels in BD participants were significantly higher (136%) than in participants without MMD (100%). The increase in DBP levels in MDD participants (121.1%) was not statistically different from these groups. The DBP responds early to cellular damage by binding of structural proteins and activating inflammatory cells. A product of enzymatic cleavage of DBP has been described as macrophage-activating factor. Circulating DBP is comprised of heterogenous high and low molecular fractions that are only partially recognized by mono- and polyclonal ELISA and are not suitable for the quantitative comparison of DBP in non-mood and MDD participants. Our data suggest DBP as a marker candidate of BD warranting its validation in a larger cohort of adolescent and adult MMD patients.
Major mood disorders (MMD), specifically bipolar disorder (BD) and major depressive disorder (MDD), are some of the most prevalent albeit under-diagnosed health problems in children and adolescents1,2. Worldwide among adolescents, MDD and BD are the first and fourth most disabling conditions, respectively3. High mortality in adults with MDD and BD is attributed to suicide and cardiovascular-related disorders4. Currently, there is an estimated 10-year delay between onset of BD and accurate diagnosis5 because robust biomarkers for MMD have not been identified.
Biomarker discovery is impeded due to the insufficient understanding of the underlying etiology and pathophysiology of MMD6. Pathophysiology of BD has been attributed to deficits in serotonin7. Microglia macrophages produce and sense serotonin in response to proinflammatory cytokines in the brain and peripheral nervous system7. MDD has been associated with a reduction in glial cell counts and density compared to healthy controls8. In contrast, activated microglia release proinflammatory cytokines in BD, thereby, exerting negative effects on the neuroprotective system and mediating further pathophysiological disturbances9. Glia maturation factor beta (GMFβ), which is expressed in cerebral astrocytes, activates the microglia10. Activated microglia release proinflammatory cytokines, which exert negative effects on the neuroprotective system and mediate further pathophysiological disturbances related to BD9. These disturbances include alterations in synaptic function as well as in apoptosis, excitotoxicity, and downregulation in neurogenesis and neurotrophin production9,11. It still unclear what processes trigger inflammation in the brain, but inflammatory signaling in the kynurenine pathway, an alternate route of tryptophan metabolism that decreases serotonin neurotransmission, as well as activation of the enzyme glycogen synthase kinase-3 beta (GSK-3β) in the Wnt pathway, and activation of cyclooxygenase 2 and arachidonic acid appear to be involved11.
Given that inflammation influences abnormalities in glia and neuronal plasticity7, systemic inflammation has also been proposed as a mechanism or a result of MMD depending on etiologies9,12,13,14. Elevated cytokine levels in peripheral blood and cerebrospinal fluid, and altered inflammatory activity are found in those with MMD compared to non-depressed individuals12,13. Specifically, tumor necrosis factor-alpha (TNF-α) is higher in adult patients with MDD15. Cytokines, such as interleukin (IL)-4, IL-6, and IL-8, are also reportedly altered in patients with MDD16,17. The elevated levels of proinflammatory cytokines in patients with MDD, who are otherwise healthy, suggest a likely link between depressive illness and dysregulation of the inflammatory response15,18,19. In addition to elevated proinflammatory cytokines, BD is also associated with hyperactivity of T-helper cell 1, with significantly higher levels in BD patients during manic and depressive episodes as compared to non-BD controls12,20,21.
Nuclear factor kappa-B (NFκB) is a key transcription factor in the regulation of increased expression of proinflammatory cytokines and neuroendocrine responses to stress22,23. Hyperactivation of NFκB in BD is also thought to be a protective mechanism against the neurotoxic effects of repeated illness episodes22,24. Despite the evidence that the inflammatory cascade is regulated by activation of NFκB23,25,26, few studies have examined NFκB regulation in MMD in pediatric-onset MDD or BD22. Manifestations of inflammation in studies of youth with MMD vary, and to date no robust marker predicting onset of MMD in an adolescent population has been reported.
The relatively new field of psychiatric nutrition has highlighted a relationship between diet and the mental health status of children and adolescents27,28,29,30,31. Vitamin D has been shown to influence inflammation-dependent disorders of the central nervous system (CNS) in multiple sclerosis32,33, amyotrophic lateral sclerosis34, and MMD35. Gracious et al.36 reported an association between vitamin D deficiency in adolescents and severity of mental illness. A pilot study of youth with BD documented both improvement of manic and depressive symptoms and normalization of brain neurochemistry via neuroimaging following an 8-week open-label trial of 2000 IU of vitamin D337. Vitamin D may participate in the regulation of brain function, as vitamin D receptors (VDR) are present in large amounts in the CNS and in the developing and mature human brain38,39. Vitamin D is transported by vitamin D-binding protein (DBP), but little is known about its role in the CNS. DBP is expressed in the rat40 and possibly in human brain41,42,43. DBP is found in human cerebrospinal fluid32,44.
DBP has three domains, with each serving a specific function42. Vitamin D vitamers are bound in the first domain42. Only 1–2% of DBP are bound to vitamin D, suggesting that DBP function extends beyond its vitamin D transport properties41,43. The second and third domain of DBP binds fatty acids42,45, extracellular structural proteins42,46, and trombospondin47, in the circulation after cell necrosis and tissue injury. The carboxy-terminal domain of DBP also contains an O-linked glycosylation site48,49. Enzymatic cleavage of this side transforms DBP into a lower molecular weight DBP-L (53.4kD)48. This DBD-L was characterized as a potent macrophage-activating factor (termed DBP-MAF)49. The potential relevance of DBP modifications to MMD pathogenesis is unknown.
In this pilot study, we tested potential blood-based markers of inflammation, NFκB activation, and vitamin D in adolescents with MMD, to better understand their contribution to MMD in youth4,14,22,50. Using a new strategy, we identified a candidate biomarker for BD that changes in response to inflammation, cell death, and vitamin D status.
Detailed description of studies, experimental procedures, and reagent information is provided in Supplementary Materials.
Plasma samples used in this study were collected from a subset of participants enrolled in the National Institute of Mental Health (NIMH) Longitudinal Assessment of Manic Symptoms (LAMS) study, which examines mood symptom changes and elevated symptoms of mania (ESM) biannually in 685 youth aged 6–12 years recruited at four sites51 The Ohio State University (OSU) Institutional Review Board approved both the LAMS study and this sub-study. Assent from the youth and informed consent from the parent were obtained prior to data collection.
Study design and clinical assessment
Clinical study procedures were conducted in the Child Mood Lab of Dr. Fristad at the OSU Wexner Medical Center Harding Hospital. Diagnostic data used in this study were obtained by post-doctoral or graduate student trained interviewers who met ongoing standards for inter-rater reliability. Mood questions from the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Episode (K-SADS-PL-W) were used to determine MMD. Interviewers were unaware of vitamin D level results at the time of the interviews.
Participants (n = 36) were grouped into three categories: Non-mood controls (n = 13), bipolar (BD) (n = 12), and MDD (n = 11). Groups were assigned based on consensus conference review led by a licensed child/adolescent psychologist. Body mass index was calculated using standardized height and weight measures. Blood was collected by OSU Clinical Research Center nursing staff.
Concentrations of inflammatory cytokine IL-6, autoantibodies to oxLDL, and vitamin D in serum as well as serum NFκB activity were measured and analyzed in conjunction with metabolic characteristics (body mass index (BMI)). All experiments except clinical vitamin D levels were performed in a ‘‘blind’’ fashion using coded information from participants.
Vitamin D detection
Vitamin D (25-hydroxycalciferol and 25-hydroxyergocalciferol) analysis on serum was performed by high-pressure liquid chromatography (HPLC) coupled with mass spectrometry (MS) detection at the Esoterix Laboratory Services, Inc. (Austin, Texas).
Immunoprecipitation and LTQ Orbitrap
Mouse anti-human GMFβ antibody (Proteintech, Rosemont, IL, USA) was conjugated on beads (Millipore, Darmstadt, Germany). Cell lysates were incubated with anti-GMFβ-conjugated beads according to manufacturers’ protocol. Proteins bound to anti-GMFβ-conjugated beads were eluted, digested, and identified by capillary-liquid chromatography-nanospray tandem mass spectrometry (Capillary-LC/MS/MS) of global protein identification was performed on a Thermo Fisher LTQ orbitrap mass spectrometer equipped with a microspray source (Michrom Bioresources Inc, Auburn, CA) operated in positive ion mode. One-hundred twenty-six proteins were identified by immunoprecipitation using anti-GMFβ antibody that were present at higher levels in serum from MMD than non-mood control group. We excluded proteins that were not present in plasma in one group of patients (Ratio 0 or n/a). The size of putative GMFβ-positive homolog (50 ± 5 kD) was determined using individual plasma samples from all patients analyzed by western blot using the same antibodies. Homology comparison was performed for proteins that had a molecular weight of 50 ± 5 kD. The remaining protein structures were analyzed for the homology to GMFβ (Accession number NP_004115.1) using NCBI BLAST program. DBP accession number used for this program was AAA61704.1.
A mouse monoclonal antibody raised against amino acids 175–474 mapping at the C-terminus of DBP of human origin (Santa Cruz Biotechnology, sc-365441) was conjugated on beads and immunoprecipitation was performed as described above. Samples were pooled from all investigated participants without mood disorders or with BD. On beads digestion and capillary-liquid chromatography-nanospray tandem mass spectrometry is described in Supplementary Materials.
Enzyme-linked immunosorbent assays (ELISA)
IL-6 serum concentrations were analyzed using Immulite 1000 IL-6 assay (Siemens Healthcare Diagnostics, Deerfield, IL) using monoclonal murine anti-IL-6 antibody (Siemens Healthcare Diagnostics, Deerfield, IL, LK6P).
Human IgG autoantibodies to oxidized low-density lipoproteins (oxLDL) in serum were measured using an Anti-Oxidized LDL (oLAB) ELISA Kit (Biomedica, Vienna, Austria).
DBP concentrations in serum were analyzed using polyclonal antibodies recognizing DBP without bound actin (Alpco, Salem, NH, USA, 30–2314) and monoclonal (DVDBP0,Quantikine ELISA, R&D Systems, Minneapolis, MN, USA) anti-DBP ELISA assays.
The plasma from all patients was diluted (1:60) to achieve the linear range for detection in western blot. The standard serum was prepared using a pool of equal volume (5 μL) from all tested plasma samples under reducing conditions. Serum samples were separated on 10% polyacrylamide gel under reducing conditions. Each western blot included standard plasma as well as plasma samples from two non-mood control, two MDD, and two BD patients. DBP was detected using rabbit monoclonal anti-DBP antibody (ab8130730 Abcam, Cambridge, MA, USA) and secondary infrared antibodies (LI-COR Biosciences Lincoln, NE, USA). Membranes were analyzed using an Odyssey Infrared Imaging System and ImageJ software. Data were normalized across membranes using the standard. Standard was prepared using equal aliquots from each participant from all three groups.
Additional western blots were performed using gradient polyacrylamide gel (4–20% Mini-PROTEAN #4561096, BioRad, Hercules, CA, USA) using original, deglycosylated/desialylated, plasma samples as well as plasma samples depleted of albumin and immunoglobulins. Albumin was removed from randomly selected individual serum samples using Pierce albumin/IgG removal kit (89875, Thermo Fisher Scientific, Waltham, MA, USA,) following the manufacturer’s protocol for human serum albumin and immunoglobulin removal. One-hundred and sixty microliters of PBS was added to each sample to create a final dilution of 1:32. Samples were then analyzed using western blot or were treated with protein deglycosylation mix II (P6044S, New England Biolabs, Ipswich, MA, USA) following the manufacturer’s protocol for denaturing reaction conditions. After desialylation and deglycosylation samples were analyzed by western blot as described above.
Pooled plasma from participants with and without BD was purified on HU-6 multiaffinity removal column (4.6 × 50 mm, P.N 5185–5084, Agilent Technologies) using manufacturer’s protocol. Fractions were collected and analyzed using dot blot. DBP was detected using antibody and procedures described in western blot.
Data was shown as mean ± standard deviation (SD). Two-tailed t-tests, R values, ANOVA one-way analysis and Tukey’s honest significance test (Tukey HSD) were used to compare differences between groups (unless otherwise stated). Normality was measured using Shapiro–Wilk Test. Correlation between normally and non-normally distributed variables was examined using Pearson’s test and Spearman Correlation, respectively. The level of significance was set at p < 0.05.
BMI is described to account for contribution of adipose tissue to proinflammatory cytokine production53. BMI was significantly lower in BD participants (Table 1, p < 0.02) compared to the MDD group. BMI in non-mood controls was not significantly different from other groups. Similar changes in BMI values have been reported in other studies among adolescent MMD participants compared to adolescents without mood disorders54,55. As expected, BMI is positively associated with IL-6 concentration in serum from all participants (Table 2, p < 0.02). Also consistent with previous studies56,57,58, we found that vitamin D concentrations in serum are inversely associated with BMI in all participants (Fig. 1, p < 0.006). In agreement with known immune functions of vitamin D56, serum vitamin D concentrations showed inverse associations when compared to inflammatory cytokine IL-6 (Table 2, p < 0.04) and autoantibodies to oxLDL, a marker of oxidative stress (Table 2, p < 0.05). Thus, adolescents with and without MMD show similar associations between obesity assessed by BMI, inflammation, and vitamin D status as documented previously in other populations13,22,53,56,57.
We also examined whether cytokines, vitamin D, and NFκB are altered in serum isolated from participants with and without MMD. We found no difference between serum vitamin D concentrations in participants from non-mood control, MMD, or BD groups (Table 1). Levels of IL-6 and autoantibodies to oxidized LDL were variable within groups and were not statistically different between participants (Table 1). Similarly, NFκB activation in reporter cells stimulated by serum from patients with and without MMD was not different among groups (Table 1). Thus, none of the major inflammatory factors or vitamin D had the power to detect differences in small groups of adolescent participants with and without MMD.
We also hypothesized that MMD pathogenesis may depend on specific inflammatory factor(s) that share properties and structural homology with inflammatory cytokines in the brain. GMFβ is an established neurotrophic and inflammatory factor implicated in activation of glia and development of the nervous system, angiogenesis, and immune function59,60. Using anti-GMFβ antibodies and the bait strategy61,62, we investigated whether serum from participants with and without MMD contains different amount of GMFβ or its protein homolog. We performed immunoprecipitation using anti-GMFβ antibodies in pooled serum from patients with and without MMD. The sequence of bound proteins to GMFβ was identified by mass spectrometry (Supplementary Table 1). Individual sample analysis by western blot showed that the weight of homologous protein was approximately 50 kD in plasma of participants with and without MMD. Next, we compared for structural homology of proteins to GMFβ. The low molecular weight vitamin D-binding protein (DBP-L, 53KD) showed 37% shared homology with GMFβ. DBP-L was present at eightfold higher levels in serum of participants with MMD compared to those without mood disorder. The structural proteins vitronectin, clusterin, and tubulins were also ~50 kD proteins homologous to GMFβ and present at higher levels in participants with MMD compared to the control group. However, in this paper we investigated DBP, given its roles in protection of nervous tissue by removing structural proteins from circulation, delivery of vitamin D, and regulation of inflammation42.
Given the qualitative nature of immunoprecipitation/sequencing, we validated and quantified the levels of DBP in serum of participants with and without MMD using western blot, mono- and polyclonal ELISA. Western blot revealed heterogenous bands (53–56 kD) including DBP-H and DBP-L, respectively in non-mood controls, MDD, and BD (Fig. 2a). The comparison of total DBP levels in serum measured by western blot showed a moderate increase in total DBP (121%) in MDD vs. non-mood controls (Fig. 2b, p = 0.13, n.s.). In the serum of BD participants total DBP (137%) levels were significantly increased compared to those in non-mood control group (Fig. 2b, p < 0.02). The immunoprecipitation using anti-DBP antibodies revealed a similar (156%) increase in DBP serum pooled from all participants with BD compared to those without this disease (Supplementary Table 2).
The removal of albumin augmented the differences between DBP in plasma from participants with and without BD (Fig. 2c). However, this procedure impedes quantitative analysis because a substantial portion of DBP is eluted with albumin (Supplementary Fig. 1) due to the structural homology of these proteins42. To examine if DBP heterogeneity is a result of its modification, we performed enzymatic delycosylation and desialylation of plasma from randomly selected participants with and without BD plasma. Gradient gel electrophoresis separated DBP in plasma as a single band (Supplementary Fig. 2A). However, the treatment with deglycosylation and desialylation enzymes produced multiple modified DBP forms in plasma from both patients with and without BD (Supplementary Fig. 2B). Thus, in this pilot study, elevated total DBP levels comprising of all modifications were associated with BD.
The heterogeneity of DBP modifications has profound impact on the outcome of DBP quantification using different methods. DBP measured by western blot was not associated with DBP measured by either monoclonal or polyclonal ELISA, suggesting that ELISA antibodies do not recognize all DBP modifications (Table 3, Supplementary Fig. 3A, B). DBP measured by monoclonal ELISA also showed no correlation with vitamin D concentration in serum in non-mood control (Fig. 3a). However, in MDD participants, but not in BD participants DBP levels recognized by polyclonal ELISA were inversely associated with vitamin D levels (Fig. 3b, p < 0.013 vs. Fig. 3c). Indirectly, this opposite trend suggests a change in DBP structure responsible for vitamin D transport in the MDD group compared to non-mood participants. It is expected, because DBP binds various ligands, including structural proteins, complement factors, vitamin D vitamers, and lipids42. DBP measured by western blot shows no significant associations with vitamin D levels in plasma (Fig. 3d–f) in agreement with evidence of vitamin D transport by approximately 2% of total DBP42. Thus, compared to western blot, ELISA appears to recognize only specific fractions of DBP that were not different among participants with and without MMD (Supplementary Figure 3C, D)
The major finding in our study is the identification of increased levels of DBP in participants with BD compared to non-mood controls. The increased levels of DBP in the circulation of adolescents with BD could be interpreted in two ways: DBP plays a role in the pathogenesis of BD in adolescents or DBP is a factor associated with this disorder.
Vitamin D has been recognized in playing an important role in reducing inflammation through immunomodulatory properties56. However, only 2% of DBP functions in the capacity of a vitamin D transporter42. Moreover, vitamin D–DBP complex has a restricted passage through the blood–brain barrier63. Another, non-vitamin D carrier role for DBP is the binding of alternative cargo ligands in response to cellular damage and subsequent activation of inflammation43. Cellular and neurocellular damage leads to release of actin43, and possibly other structural proteins64. Binding of actin to GMFβ65 in the brain and to DBP in the cerebrospinal fluid and circulation prevents actin polymerization, aggregation, and activation of the coagulation cascade. In multiple sclerosis, DBP concentrations in the cerebrospinal fluid serve as a biomarker for this disease32,66. Recent investigations demonstrate that defects in actin polymerization may also be an underlying course of BD pathology67,68, whereas mutations in β-tubulin underlie axonal damage69. Moreover, stabilization of the cytoskeleton is a major basis for lithium, valproate, and paliperidone therapies67,68. Additionally, transcriptome analysis of post-mortem brain tissues from participants with and without schizophrenia or BD also highlights the cytoskeleton as a central deranged pathway in these disorders70. In our immunoprecipitation experiments, we found 35-fold increased levels of actin and other structural proteins such as tubulins, actin, actinin, or multimerin in serum from participants with BD vs. non-mood controls. However, it remains to be investigated whether DBP binds these structural proteins, or whether structural proteins were recognized by anti-DBP antibody nonspecifically in serum from participants with BD compared to non-mood controls (Supplemental Tables 1 and 2). These structural proteins required testing as candidate markers for BD in addition to DBP. In previous studies, DBP levels appear to indicate an early pathological manifestation of diseases linked to the cytoskeleton damage as a biomarker32,66. BD is results in derangements of the cytoskeletons67,68 and elevated concentrations of DBP in BD may indicate these detrimental changes.
DBP is also closely related to inflammatory processes, which were thoroughly investigated for their role in BD and MDD in the context of major inflammatory markers such as IL-6, MCP1, and TNFα9,12,14,21. In our study, IL-6, showed no significant changes among the different groups. Elevated IL-6 levels in circulation accompanies many proinflammatory conditions including obesity71. We found a significant correlation between plasma levels of IL-6 and BMI across all studied groups. These results suggest that obesity and probably other unaccounted inflammatory processes in these study participants contributed to chronic inflammation more than those activated by neurocellular damage.
DBP has a principally different mode of inflammatory action responding to early changes in damaged cellular membranes32 or to extracellular actin72. DBP binds lysophosphotidylcholine (Lyso-Pc) with a high affinity73,74. Lyso-Pc is a lipid mediator of acute and chronic inflammation in peripheral organs and nervous system in response to oxidative damage, inflammation, extracellular actin or changes in the intracellular actin network72,75. Binding of lyso-PC in the presence of T and B cells activates cleavage of DBP to DBP-L74, which can then activate macrophages in various diseases (DBP-MAF reviewed in ref. 42). In our study, we found significantly elevated DBP levels in participants with BD compared to non-mood controls, using western blot recognizing multiple forms of DBP. In contrast, ELISA using polyclonal anti-DBP antibodies, appear to recognize only DBP forms associated with decreased vitamin D transport in MDD participants. Similar prognostic changes were reported in patients with multiple sclerosis66. Classic conditions associated with inflammation including IL-6 levels in plasma, NFκB activation, or obesity were similar in participants with and without MMD in our study. These findings suggest DBP as a more suitable marker of BD pathology than inflammatory cytokines. More studies also need to investigate binding partners of DBP, especially lipid mediators, leading to its cleavage in BD. It additionally remains unclear whether the DBP-L molecule is a macrophage-activating factor augmenting inflammation and pathogenesis of BD. Other proteins immunoprecipitated with anti-GMFβ or anti-DBP should also be studied as potential biomarkers of MDD. Despite of these unknowns, in this pilot investigation, DBP appears to significantly change in response to BD pathogenesis and needs to be tested as a candidate marker for BD in a large cohort of adolescents and adults in the future.
The important methodological outcome of our study is the direct comparison of different tools for DBP measurement, including monoclonal and polyclonal anti-DBP based ELISA, proteomic and western blot analysis. We found that total DBP comprising of DBP-H and DBP-L forms can only be detected with western blot and proteomics. The binding of different cargo molecules to DBP42,43 in participants with and without MDD changes the affinity to antibodies in ELISA that obscure measurements. Reducing conditions in western blot lead to dissociation of cargo molecules from DBP and allow detection of heterogenous DBP-L and DBP-H modifications. Similar ELISA paradoxes have been reported in other studies76. DBP was significantly lower in African Americans vs. Caucasians when measured using a monoclonal antibody-based ELISA, but higher with a polyclonal anti-DBP ELISA76. In contrast, groups applying proteomic analysis to study cerebrospinal fluid from patients with multiple sclerosis found two modifications of DBP66 that were changed in opposite direction in multiple sclerosis patient with a different clinical course, suggesting them as new candidate prognostic biomarkers of disease aggressiveness. Our study, suggests that conclusive data on DBP function can be obtained only using proteomics and/or western blot methods.
Distinguishing BD from unipolar MDD early in the onset of illness can lead to more appropriately specific intervention, which has the potential to improve quality of life, reduce psychosocial morbidities, and recurrent mood episodes. The latter convey increased risk for suicide and for physical comorbidities, especially in adolescent patients4,50. Genetic, dietary, and inflammatory factors influence the pathogenesis of BD and development of the CNS77. DBP integrates responses to neuronal cell death, activation of inflammatory cascade, and vitamin D and lipid status40,41,42,43,49,66,74,78,79. Thus, DBP holds promise as a diagnostic biomarker changing in response to all major factors contributing to pathogenesis of BD, and may shed light on BD pathophysiologic mechanisms.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The project was supported by Accelerator Award from the Technology and Commercialization Office at the Ohio State University (OZ), and NIH grants R01 MH073801 (M.F., L.E.A.), R21OD017244 (O.Z., B.P., K.Y.), the National Center for Research Resources UL1RR025755, UL1TR001070, and NCI P30CA16058 (OSUCCC), and the NIH Roadmap for Medical Research. Dr. Gracious’ time and costs of the blood draw, supplies, and vitamin D assays were funded by the NCH/OSU Dept. of Psychiatry and Behavioral Health Jeffrey Research Fellowship and The Research Institute at Nationwide Children’s Hospital, respectively. We would like to give a special thank you to Dr. Liwen Zhang (OSU) for proteomic analysis support.